TrialHaematologica2026

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Elias Jabbour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.